FIELD: chemistry.
SUBSTANCE: invention relates to novel crystalline forms of 3-[[3,5-dribromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-3-oxopropanoic acid, characterised by X-ray powder diffraction pattern with principal peaks either at 2θ = 16.1 ± 0.2, 20.1 ± 0.2, 20.7 ± 0.2, and 24.2 ± 0.2, or at 2θ = 9.0 ± 0.2, 14.7 ± 0.2, 19.6 ± 0.2, 21.6 ± 0.2 and 24.3 ± 0.2. The invention also relates to methods of obtaining the disclosed crystalline forms, a pharmaceutical composition having thyroid beta-receptor agonist properties, a method for selective agonist action on thyroid beta-receptor, use of said forms to produce a medicinal agent and a method of treating mammals suffering from thyroid dysfunction associated conditions.
EFFECT: obtaining novel crystalline forms of 3-[[3,5-dribromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-3-oxopropanoic acid, having thyroid beta-receptor agonist properties.
19 cl, 3 tbl, 7 ex
| Title |
Year |
Author |
Number |
| METHOD OF PURIFYING A BENZOPYRAN DERIVATIVE, ITS CRYSTALLINE FORM AND A METHOD OF PRODUCING A CRYSTALLINE FORM |
2016 |
- Ryu Jae-Chun
- Park Yong-Kyun
- Kim Hyun-Kyu
- Shin Dong-Yeop
|
RU2729074C2 |
| SALT OF ARYLAMINOQUINAZOLINE-CONTAINING COMPOUND AND METHOD FOR PREPARATION AND USE THEREOF |
2021 |
- Zhou Fugang
- He Yuxia
- Zhang Yan
- Lyu Jian
- Shi Kai
- Di Huifeng
- Yang Xinxin
- Sun Jing
|
RU2833198C1 |
| CRYSTALS OF ALKYNYL-CONTAINING COMPOUND, SALT AND SOLVATE THEREOF, METHOD OF PRODUCTION AND WAYS OF APPLICATION THEREOF |
2021 |
- Wen, Jianfeng
- Lin, Yanqiong
- Feng, Jianpeng
- Wu, Tianzhu
- Shao, Zhenzhong
- Li, Weidong
|
RU2829609C1 |
| AMORPHOUS 42-ESTER OF RAPAMYCIN AND 3-HYDROXY-2(HYDROXYMETHYL)-2-METHYLPROPANOIC ACID AND PHARMACEUTICAL COMPOSITIONS CONTAING IT |
2004 |
- Bendzhamin Ehrik Dzh.
- Ashraf Mukhammad
- Dzhain Ashvinkumar
|
RU2345999C2 |
| CRYSTALLINE POLYMORPH OF 2-[4-[2-[[(1S,2R)-2-HYDROXY-2-(4-HYDROXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]PHENOXY]ACETIC ACID |
2000 |
- Toda Mitio
- Tamai Tetsuro
- Tanaka Nobujuki
- Kasai Kiesi
- Sonekhara Dzuniti
- Tsuru Ehjdzi
|
RU2237656C2 |
| 7-[3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYL-PENT-1-ENYL)-CYCLOPENTYL]-N-ETHYL-HEPT-5-ENEAMIDE (BIMATOPROST) IN CRYSTALLINE FORM II, METHODS OF THEREOF OBTAINING AND METHODS FOR APPLICATION THEREOF |
2010 |
- Embras Dzhiordzhi F.
- Kejrami Kajomars
- Vu Ke
|
RU2577546C2 |
| LOBAPLATIN CRYSTALS, METHODS OF PRODUCTION AND APPLICATIONS IN PHARMACEUTICALS |
2014 |
- Dou, Qiling
- Sui, Donghu
- Zhang, Shenggui
|
RU2648990C1 |
| CRYSTALLINE FORMS OF BTK INHIBITOR |
2020 |
- Angst, Daniela
- Kordikowski, Andreas
|
RU2828460C2 |
| CRYSTALLINE FORMS OF LTA4H INHIBITOR |
2019 |
- Kordikowski, Andreas
- Wu, Yanxiang
|
RU2808992C2 |
| SALT AND CRYSTALLINE FORM OF COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY |
2020 |
- Otani, Shuhei
- Fujito, Takayuki
- Imura, Naoko
- Kijima, Hideomi
- Parent, Stephan D.
- Bevill, Melanie Janelle
- Johnson, Courtney S.
- Houston, Travis Lee
|
RU2833357C2 |
